Cybin Files its 13th Patent Application and Announces Digital Therapeutics Strategy
July 13 2021 - 7:23AM
InvestorsHub NewsWire
TORONTO, Canada -- July 13, 2021 -- InvestorsHub NewsWire
-- Cybin Inc. (NEO:CYBN)
(OTCQB:CLXPF)
("Cybin" or the "Company"), a
biotechnology company focused on progressing psychedelic
therapeutics, today announced that it has filed its 13th new
provisional patent application and has advanced the build-out of
its digital therapeutics strategy.
The company is evolving its programs beyond the psychedelic
molecule, into an eco-system that may potentially drive improved
patient treatments through the advancement of its digital
therapeutics development.
Led by Cybin's innovation team, including its newly formed
patient steering committee, Cybin has commenced the next phase of
the company's digital therapeutics platform which will better
enable the evaluation of patient outcomes through a highly secure,
patient-centered data analytics platform for better pre- and post-
psychedelic treatments.
The digital therapeutics platform, which is proprietary to Cybin
and the subject of the company's 13th patent
application, adds another dimension to the company's development
programs. The aim of utilizing and leveraging cutting-edge
technologies to support drug development candidates will be a top
priority as both the industry and the company evolves.
Combined with the company's recently announced collaboration
with Kernel (quantitative neuroimaging technology), Greenbrook TMS
(operator of 129 outpatient mental health service centers in the
United States), and the progression of other proprietary tools such
as the EMBARK psychotherapy model, Cybin is building an advanced
eco-system that can drive innovation from the psychedelic molecule,
delivery of the molecule, quantitative testing of the molecule in
patients to late-stage trials and one day potential patient
treatments.
About Cybin
Cybin is a leading biotechnology company focused on progressing
psychedelic therapeutics by utilizing proprietary drug discovery
platforms, innovative drug delivery systems, novel formulation
approaches and treatment regimens for psychiatric disorders.
Cautionary Notes and Forward-Looking
Statements
Certain statements in this news release related to the Company
are forward-looking statements and are prospective in nature.
Forward-looking statements are not based on historical facts, but
rather on current expectations and projections about future events
and are therefore subject to risks and uncertainties which could
cause actual results to differ materially from the future results
expressed or implied by the forward-looking statements. These
statements generally can be identified by the use of
forward-looking words such as "may", "should", "could", "intend",
"estimate", "plan", "anticipate", "expect", "believe" or
"continue", or the negative thereof or similar variations.
Forward-looking statements in this news release include statements
regarding enhanced liquidity, the value of additional capital
markets exposure, access to institutional and retail investors, the
Company's new strategic brand messaging campaign, and psychedelic
drug development programs to potentially treat mental health
disorders. There are numerous risks and uncertainties that could
cause actual results and Cybin's plans and objectives to differ
materially from those expressed in the forward-looking information.
Actual results and future events could differ materially from those
anticipated in such information. These and all subsequent written
and oral forward-looking information are based on estimates and
opinions of management on the dates they are made and are expressly
qualified in their entirety by this notice. Except as required by
law, the Company does not intend to update these forward-looking
statements.
Cybin makes no medical, treatment or health benefit claims about
Cybin's proposed products. The U.S. Food and Drug Administration,
Health Canada or other similar regulatory authorities have not
evaluated claims regarding psilocybin, psychedelic tryptamine,
tryptamine derivatives or other psychedelic compounds or
nutraceutical products. The efficacy of such products have not been
confirmed by approved research. There is no assurance that the use
of psilocybin, psychedelic tryptamine, tryptamine derivatives or
other psychedelic compounds or nutraceuticals can diagnose, treat,
cure or prevent any disease or condition. Vigorous scientific
research and clinical trials are needed. Cybin has not conducted
clinical trials for the use of its proposed products. Any
references to quality, consistency, efficacy and safety of
potential products do not imply that Cybin verified such in
clinical trials or that Cybin will complete such trials. If Cybin
cannot obtain the approvals or research necessary to commercialize
its business, it may have a material adverse effect on Cybin's
performance and operations.
The NEO Exchange has neither approved nor disapproved the
contents of this news release and is not responsible for the
adequacy and accuracy of the contents herein.
Contacts
Investor Contacts:
Tim Regan/Scott Eckstein
KCSA Strategic Communications
Cybin@kcsa.com
Lisa M. Wilson
In-Site Communications, Inc.
lwilson@insitecony.com
Media Contacts:
John Kanakis
Cybin Inc.
John@cybin.com
Cybin (NEO:CYBN)
Historical Stock Chart
From May 2024 to Jun 2024
Cybin (NEO:CYBN)
Historical Stock Chart
From Jun 2023 to Jun 2024